These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 410034)

  • 21. [Humoral mechanisms of in vitro inhibition of mouse lymphocyte immunoreactivity by mastocytoma P815 cells].
    Medvedev AE
    Biull Eksp Biol Med; 1988 Jun; 105(6):701-3. PubMed ID: 2968820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B-lymphocyte mediated cytolysis: a complement independent phenomenon.
    Henney CS; Clayburgh J; Cole GA; Prendergast RA
    Immunol Commun; 1972; 1(1):93-103. PubMed ID: 4197435
    [No Abstract]   [Full Text] [Related]  

  • 23. Pretreatment of P815 mastocytoma cells with inhibitors of protein synthesis reduces their susceptibility to lysis by cytotoxic thymus-derived lymphocytes.
    D'Angeac AD; Hale AH
    Cell Immunol; 1980 Oct; 55(2):342-54. PubMed ID: 6775821
    [No Abstract]   [Full Text] [Related]  

  • 24. Murine macrophage cytotoxicity induced by mastocytoma cells, cell-free mastocytoma exudates, and extracts.
    Dullens HF; Den Otter W
    Immunopharmacology; 1981 Sep; 3(3):241-51. PubMed ID: 6796544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A specific helper factor which enhances the cytotoxic response to a syngeneic tumour.
    Kilburn DG; Talbot FO; Teh HS; Levy JG
    Nature; 1979 Feb; 277(5696):474-6. PubMed ID: 105295
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro and in vivo production of chemotactic inhibitors by tumor cells.
    Cohen MC; Brozna JP; Ward PA
    Am J Pathol; 1979 Mar; 94(3):603-14. PubMed ID: 106732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mastocytoma-medicated suppression of mixed lymphocyte culture and mitogen responsiveness.
    DeLustro F; Argyris BF
    Cell Immunol; 1976 Jan; 21(1):177-84. PubMed ID: 129285
    [No Abstract]   [Full Text] [Related]  

  • 28. A multiple-parameter comparison of immunocompetence and tumor resistance in aged BALB/c mice.
    Perkins EH; Cacheiro LH
    Mech Ageing Dev; 1977; 6(1):15-24. PubMed ID: 13249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of the immune response in vitro and in vivo by splenocytes from tumor-bearing mice.
    Specter SC; Kamo I; Friedman H
    Adv Exp Med Biol; 1976; 66():457-63. PubMed ID: 817575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-associated immunosuppressive factors.
    Friedman H; Secter S; Kamo I; Kateley J
    Ann N Y Acad Sci; 1976; 276():417-30. PubMed ID: 829207
    [No Abstract]   [Full Text] [Related]  

  • 31. Noncytotoxic IgE-mediated release of histamine and serotonin from murine mastocytoma cells.
    Taurog JD; Mendoza GR; Hook WA; Siraganian RP; Metzger H
    J Immunol; 1977 Nov; 119(5):1757-61. PubMed ID: 72105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mastocytoma cell migration in vitro: inhibition by MIF-containing supernatants.
    Cohen MC; Zeschke R; Bigazzi PE; Yoshida T; Cohen S
    J Immunol; 1975 May; 114(5):1641-3. PubMed ID: 164509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytostatic effect of macrophages from non-immunised mice on mastocytoma P-815 cells in vitro.
    Bandlow G; Gröner R
    J Cancer Res Clin Oncol; 1979 Jul; 94(3):225-32. PubMed ID: 113416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor bearer T cells suppress BCG-potentiated antitumor responses II. Characteristics of the efferent phase suppressor.
    Hawrylko E; Mele CA; Stutman O
    Cell Immunol; 1982 Jan; 66(1):139-51. PubMed ID: 6805960
    [No Abstract]   [Full Text] [Related]  

  • 35. [Virus infected lymphoblasts acting as antigen for the production of heterologous antilymphocyte sera].
    Bandlow G; Kieling F; Thomssen R
    Med Microbiol Immunol; 1972; 157(4):335-45. PubMed ID: 4343424
    [No Abstract]   [Full Text] [Related]  

  • 36. Cytotoxic T cell responses to a syngeneic tumour: conditions for primary activation in vitro.
    Warren HS; Woolnough JA; Lafferty KJ
    Aust J Exp Biol Med Sci; 1978 Apr; 56(2):247-51. PubMed ID: 98140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macrophage-mediated cytotoxicity against allogeneic target cells in vitro.
    Lohmann-Matthes ML; Schipper H; Fischer H
    Eur J Immunol; 1972 Feb; 2(1):45-9. PubMed ID: 4263647
    [No Abstract]   [Full Text] [Related]  

  • 38. Augmentation of B-cell responsiveness by a tumor-activated T-cell factor.
    Behforouz NC; Cerny J; Eardley DD
    Cell Immunol; 1983 Jul; 79(1):110-24. PubMed ID: 6407762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor cell threshold required for suppression of macrophage inflammation.
    Normann SJ
    J Natl Cancer Inst; 1978 May; 60(5):1091-6. PubMed ID: 417187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enucleated target cells are susceptible to lymphocyte-mediated cytolysis.
    Court WS; Lindquist RR
    Transplantation; 1979 Oct; 28(4):351-3. PubMed ID: 116402
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.